Prioritizing therapeutic targets using patient-derived xenograft models

K. A. Lodhia, A. M. Hadley, P. Haluska, C. L. Scott

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Effective systemic treatment of cancer relies on the delivery of agents with optimal therapeutic potential. The molecular age of medicine has provided genomic tools that can identify a large number of potential therapeutic targets in individual patients, heralding the promise of personalized treatment. However, determining which potential targets actually drive tumor growth and should be prioritized for therapy is challenging. Indeed, reliable molecular matches of target and therapeutic agent have been stringently validated in the clinic for only a small number of targets. Patient-derived xenografts (PDXs) are tumor models developed in immunocompromised mice using tumor procured directly from the patient. As patient surrogates, PDX models represent a powerful tool for addressing individualized therapy. Challenges include humanizing the immune system of PDX models and ensuring high quality molecular annotation, in order to maximize insights for the clinic. Importantly, PDX can be sampled repeatedly and in parallel, to reveal clonal evolution, which may predict mechanisms of drug resistance and inform therapeutic strategy design.

Original languageEnglish (US)
Pages (from-to)223-234
Number of pages12
JournalBiochimica et Biophysica Acta - Reviews on Cancer
Volume1855
Issue number2
DOIs
StatePublished - Apr 1 2015

Fingerprint

Heterografts
Therapeutics
Neoplasms
Clonal Evolution
Molecular Medicine
Drug Resistance
Immune System
Growth

Keywords

  • Genomics
  • Patient-derived xenografts
  • Personalized medicine
  • Targeted therapy
  • Therapeutic targets

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Genetics

Cite this

Prioritizing therapeutic targets using patient-derived xenograft models. / Lodhia, K. A.; Hadley, A. M.; Haluska, P.; Scott, C. L.

In: Biochimica et Biophysica Acta - Reviews on Cancer, Vol. 1855, No. 2, 01.04.2015, p. 223-234.

Research output: Contribution to journalArticle

Lodhia, K. A. ; Hadley, A. M. ; Haluska, P. ; Scott, C. L. / Prioritizing therapeutic targets using patient-derived xenograft models. In: Biochimica et Biophysica Acta - Reviews on Cancer. 2015 ; Vol. 1855, No. 2. pp. 223-234.
@article{dbdb6eea77064959acd6674936d29a71,
title = "Prioritizing therapeutic targets using patient-derived xenograft models",
abstract = "Effective systemic treatment of cancer relies on the delivery of agents with optimal therapeutic potential. The molecular age of medicine has provided genomic tools that can identify a large number of potential therapeutic targets in individual patients, heralding the promise of personalized treatment. However, determining which potential targets actually drive tumor growth and should be prioritized for therapy is challenging. Indeed, reliable molecular matches of target and therapeutic agent have been stringently validated in the clinic for only a small number of targets. Patient-derived xenografts (PDXs) are tumor models developed in immunocompromised mice using tumor procured directly from the patient. As patient surrogates, PDX models represent a powerful tool for addressing individualized therapy. Challenges include humanizing the immune system of PDX models and ensuring high quality molecular annotation, in order to maximize insights for the clinic. Importantly, PDX can be sampled repeatedly and in parallel, to reveal clonal evolution, which may predict mechanisms of drug resistance and inform therapeutic strategy design.",
keywords = "Genomics, Patient-derived xenografts, Personalized medicine, Targeted therapy, Therapeutic targets",
author = "Lodhia, {K. A.} and Hadley, {A. M.} and P. Haluska and Scott, {C. L.}",
year = "2015",
month = "4",
day = "1",
doi = "10.1016/j.bbcan.2015.03.002",
language = "English (US)",
volume = "1855",
pages = "223--234",
journal = "Biochimica et Biophysica Acta - Reviews on Cancer",
issn = "0304-419X",
publisher = "Elsevier",
number = "2",

}

TY - JOUR

T1 - Prioritizing therapeutic targets using patient-derived xenograft models

AU - Lodhia, K. A.

AU - Hadley, A. M.

AU - Haluska, P.

AU - Scott, C. L.

PY - 2015/4/1

Y1 - 2015/4/1

N2 - Effective systemic treatment of cancer relies on the delivery of agents with optimal therapeutic potential. The molecular age of medicine has provided genomic tools that can identify a large number of potential therapeutic targets in individual patients, heralding the promise of personalized treatment. However, determining which potential targets actually drive tumor growth and should be prioritized for therapy is challenging. Indeed, reliable molecular matches of target and therapeutic agent have been stringently validated in the clinic for only a small number of targets. Patient-derived xenografts (PDXs) are tumor models developed in immunocompromised mice using tumor procured directly from the patient. As patient surrogates, PDX models represent a powerful tool for addressing individualized therapy. Challenges include humanizing the immune system of PDX models and ensuring high quality molecular annotation, in order to maximize insights for the clinic. Importantly, PDX can be sampled repeatedly and in parallel, to reveal clonal evolution, which may predict mechanisms of drug resistance and inform therapeutic strategy design.

AB - Effective systemic treatment of cancer relies on the delivery of agents with optimal therapeutic potential. The molecular age of medicine has provided genomic tools that can identify a large number of potential therapeutic targets in individual patients, heralding the promise of personalized treatment. However, determining which potential targets actually drive tumor growth and should be prioritized for therapy is challenging. Indeed, reliable molecular matches of target and therapeutic agent have been stringently validated in the clinic for only a small number of targets. Patient-derived xenografts (PDXs) are tumor models developed in immunocompromised mice using tumor procured directly from the patient. As patient surrogates, PDX models represent a powerful tool for addressing individualized therapy. Challenges include humanizing the immune system of PDX models and ensuring high quality molecular annotation, in order to maximize insights for the clinic. Importantly, PDX can be sampled repeatedly and in parallel, to reveal clonal evolution, which may predict mechanisms of drug resistance and inform therapeutic strategy design.

KW - Genomics

KW - Patient-derived xenografts

KW - Personalized medicine

KW - Targeted therapy

KW - Therapeutic targets

UR - http://www.scopus.com/inward/record.url?scp=84925682623&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84925682623&partnerID=8YFLogxK

U2 - 10.1016/j.bbcan.2015.03.002

DO - 10.1016/j.bbcan.2015.03.002

M3 - Article

VL - 1855

SP - 223

EP - 234

JO - Biochimica et Biophysica Acta - Reviews on Cancer

JF - Biochimica et Biophysica Acta - Reviews on Cancer

SN - 0304-419X

IS - 2

ER -